Companies - Probiodrug

Price

 
Price
€ 3,30
Change
-
Change %
-
Open
€ 3,30
High
€ 3,45
Low
€ 3,30
Volume
18.322

Profile

 
Profile
Probiodrug AG is a biopharmaceutical company dedicated to the research and development of new therapeutic products for the treatment of Alzheimer’s disease (“AD”). Headquartered in Halle, Germany, Probiodrug was founded in 1997 by Prof Dr Hans-Ulrich Demuth and Dr Konrad Glund and successfully developed a novel therapeutic concept for diabetes – the DP4 inhibitors / gliptins. Today Probiodrug’s aim is to become a leading company in the development of Alzheimer’s treatments and to thereby provide a better life for patients. Probiodrug has identified a new therapeutic concept linked to disease initiation and progression. The development approaches are targeting pyroglutamate-Abeta (pGlu-Abeta) as a therapeutic strategy to fight AD.
Industry
Biotechnology
Description
Companies in the biotechnology industry are performing research and development activities for the purpose of discovering new drugs and diagnostics. The turnover of these companies comes from sales of these products or the sale of licenses of drugs and diagnostic to other companies.

Key figures (2017)

 
The ratios below are calculated using the last known share price and the last known company financials.

Ratios per share

Price to Earnings
-3,382
Price to Earnings (3 years)
-2,263
Price to Earnings (5 years)
-2,355
Price to earnings growth
-0,244
Price/cashflow
-3,382
Price/net cashflow
-2,350
Price/book value
-
Price to sales
-

Ratios for dividend

Dividend yield
-
Pay out
-

Valuation ratios

Market value/PE
-
Market value/turnover
-
Enterprise value/turnover
-

Return ratios

Return on private equity
-
Return on total equity
-74,44%
Profit margin
-

Risk ratios

Solvability
-
Solvability
-
Current ratio
15,955
Debt to Equity
-

Value invest ratios

Grahams Number
-
Grahams Value
-
Grahams Product
-
Grahams Product (3 years)
-

2017

 

Profit and loss

Net profit (x 1 mln)
€ -8,01
Turnover (x 1 mln)
-
Cashflow(x 1 mln)
€ -8,01
Net cashflow(x 1 mln)
€ -11,53

Balance

Private equity (x 1 mln)
-
Foreign equity (x 1 mln)
-
Current assets (x 1 mln)
€ 10,69
Current liabilities (x 1 mln)
€ 0,67
Working capital (x 1 mln)
€ 10,02
Balance total (x 1 mln)
€ 10,76

Share

Outstanding shares (x 1 mln)
8,210
Price year-end
€ 10,60
Dividend per share
-
Earnings per share
€ -0,98
Cashflow per share
€ -0,98
Net cashflow per share
€ -1,40
Book value per share
-
Stockmarket value (x 1 mln)
€ 87,03

History

 
Year
2017
2016
2015
2014
2013
Net profit (x 1 mln)
€ -8,01
€ -14,51
€ -13,40
€ -11,84
€ -9,77
Turnover (x 1 mln)
-
€ 0,09
€ 0,04
€ 0,06
€ 0,75
Price year-end
€ 10,60
€ 18,03
€ 24,75
€ 19,15
-
Year high
€ 19,25
€ 27,73
€ 26,25
€ 25,00
-
Year low
€ 10,52
€ 15,00
€ 17,50
€ 15,50
-
Outstanding shares (x 1 mln)
8,210
8,187
6,872
4,862
4,255
Price to Earnings
-10,865
-10,170
-12,690
-7,864
-
Earnings per share
€ -0,98
€ -1,77
€ -1,95
€ -2,44
€ -2,30
Dividends
-
-
-
-
-
Dividend yield
-
-
-
-
-
Pay out
-
-
-
-
-
Private equity (x 1 mln)
-
€ 16,85
€ 16,13
€ 15,97
€ -4,30
PE per share
-
€ 2,06
€ 2,35
€ 3,28
€ -1,01
Balance total (x 1 mln)
€ 10,76
€ 22,37
€ 21,87
€ 21,48
€ 6,28
Stockmarket value (x 1 mln)
€ 87,03
€ 147,57
€ 170,05
€ 93,11
-

Company analysis

 

Analysis of profit indicators

Average profit per share (4 years)
€ -2,36
Standard deviation average profit
€ 0,78 (-33,04%)
Average annual growth rate
13,84%
Compound annual growth percentage
12,03%
© 2009 Skuzet. All Rights Reserved.